公开(公告)号：US20250114307A1

公开(公告)日：2025-04-10

申请号：US18987494

申请日：2024-12-19

Applicant: CureVac SE

Inventor： Fabian Johannes EBER ,  Benyamin YAZDAN PANAH ,  Stefanie SEWING ,  Thomas KETTERER ,  Thorsten MUTZKE ,  Tilmann ROOS ,  Michael SONNTAG ,  Michael WIGGENHORN ,  Katharina KOLLAND

IPC: A61K9/16 ,  A61K39/00 ,  A61K39/145 ,  A61K48/00 ,  A61P31/00 ,  A61P31/04 ,  A61P31/12 ,  A61P33/02 ,  A61P35/00 ,  A61P37/06 ,  A61P37/08

Abstract: The present invention is directed to a storage-stable formulation of long-chain RNA. In particular, the invention concerns a dry powder composition comprising a long-chain RNA molecule. The present invention is furthermore directed to methods for preparing a dry powder composition comprising a long-chain RNA molecule by spray-drying. The invention further concerns the use of such a dry powder composition comprising a long-chain RNA molecule in the preparation of pharmaceutical compositions and vaccines, to a method of treating or preventing a disorder or a disease, to first and second medical uses of such a dry powder composition comprising a long-chain RNA molecule and to kits, particularly to kits of parts, comprising such a dry powder composition comprising a long-chain RNA molecule.

公开(公告)号：US20240150386A1

公开(公告)日：2024-05-09

申请号：US18320598

申请日：2023-05-19

Applicant: CureVac SE

Inventor： Stefan HEINZ ,  Tilmann ROOS ,  Dominik VAHRENHORST ,  Markus CONZELMANN

IPC: C07H1/06 ,  A61K31/713

CPC classification number: C07H1/06 ,  A61K31/713

Abstract: The present invention is directed to a method for modifying the retention time of RNA on a chromatographic column. The present invention also concerns a method for purifying RNA from a mixture of at least two RNA species. Furthermore, the present invention relates to a method for co-purifying at least two RNA species from a mixture of at least two RNA species. In particular, the present invention provides a method for harmonizing the numbers of A and/or U nucleotides in at least two RNA species. The present invention is also directed to RNA obtainable by said methods, a composition comprising said RNA or a vaccine comprising said RNA and methods for producing such RNA and compositions. Further, the invention concerns a kit, particularly a kit of parts, comprising the RNA, composition or vaccine. The invention is further directed to a method of treating or preventing a disorder or a disease, first and second medical uses of the RNA, composition and vaccine. Moreover, the present invention concerns a method for providing an adapted RNA sequence or an adapted RNA mixture.

公开(公告)号：US20240100142A1

公开(公告)日：2024-03-28

申请号：US18315781

申请日：2023-05-11

Applicant: CureVac SE

Inventor： Tilmann ROOS ,  Martin KUNZE ,  Benyamin YAZDAN PANAH ,  Salih YILMAZ ,  Markus CONZELMANN

IPC: A61K39/12 ,  A61P21/00 ,  A61P31/00 ,  A61P39/00 ,  C07K14/005 ,  C12N15/10 ,  C12Q1/6844 ,  C40B40/02 ,  C40B40/08

CPC classification number: A61K39/12 ,  A61P21/00 ,  A61P31/00 ,  A61P39/00 ,  C07K14/005 ,  C12N15/1024 ,  C12Q1/6844 ,  C40B40/02 ,  C40B40/08 ,  A61K2039/53

Abstract: The invention relates to a method for producing a ribonucleic acid (RNA) molecule composition comprising n different RNA molecule species, the method comprising a step of RNA in vitro transcription of a mixture of m different deoxyribonucleic acid (DNA) molecule species in a single reaction vessel in parallel, i.e. simultaneously, and a step of obtaining the RNA molecule composition. Also provided is the RNA composition provided by the inventive method and a pharmaceutical composition comprising the same as well as a pharmaceutical container. Moreover, the invention provides the RNA composition and the pharmaceutical composition for use as medicament.

公开(公告)号：US20240299309A1

公开(公告)日：2024-09-12

申请号：US18258552

申请日：2021-12-13

Applicant: CureVac SE

Inventor： Michael SONNTAG ,  Tilmann ROOS ,  Stefan ARNOLD ,  Christoph ERBACHER

IPC: A61K9/51 ,  A61K39/00 ,  A61K39/215 ,  A61P37/04

CPC classification number: A61K9/5123 ,  A61K39/215 ,  A61P37/04 ,  A61K2039/545

Abstract: The invention is inter alia directed to a pharmaceutical composition or vaccine for multidose administration comprising lipid-based carriers encapsulating an RNA, wherein the composition comprises at least one antimicrobial preservative selected from an aromatic alcohol, a sugar alcohol, thiomersal, or a combination thereof. The present invention is also directed to a kit or kit of parts for preparing and/or administering the pharmaceutical composition or vaccine for multidose administration. Also provided are methods of treating or preventing a disorders or a diseases, and first and second medical uses of the pharmaceutical composition or vaccine. Further provided is the use of aromatic alcohols, sugar alcohols, and/or thiomersal for preserving and/or preparing a composition or vaccine comprising lipid-based carriers encapsulating an RNA.

公开(公告)号：US20230295709A1

公开(公告)日：2023-09-21

申请号：US18057959

申请日：2022-11-22

Applicant: CureVac SE

Inventor： Benyamin YAZDAN PANAH ,  Tilmann ROOS ,  Veronika WAGNER ,  Carola PONGRATZ

IPC: C12Q1/6865 ,  C12Q1/6806

CPC classification number: C12Q1/6865 ,  C12Q1/6806 ,  C12Q2520/00 ,  C12Q2531/113

Abstract: The present invention is concerned with linear double stranded DNA, which is coupled to a single support or a tag at the 3′ end of its non-coding strand and methods for producing said linear double stranded DNA. The present invention further relates to the use of said linear double stranded DNA in an RNA in vitro transcription reaction and also to a method for producing RNA in vitro. The present invention also relates to a bioreactor for RNA in vitro transcription.

公开(公告)号：US20230227881A1

公开(公告)日：2023-07-20

申请号：US18154437

申请日：2023-01-13

Applicant: CureVac SE

Inventor： Tilmann ROOS ,  Benyamin YAZDAN PANAH ,  Markus CONZELMANN ,  Andreas THESS ,  Dominik BUOB ,  Martin KUNZE ,  Veronika WAGNER

IPC: C12P19/34 ,  C12N9/10 ,  C12N9/16 ,  C12N9/12 ,  C12N11/02 ,  C12N11/087 ,  C12N11/098

CPC classification number: C12P19/34 ,  C12N9/1007 ,  C12Y201/01057 ,  C12Y201/01056 ,  C12Y301/03033 ,  C12N9/16 ,  C12Y207/0705 ,  C12N9/1241 ,  C12N11/02 ,  C12N11/087 ,  C12N11/098

Abstract: The present invention relates to an immobilized capping enzyme, preferably an immobilized Vaccinia virus capping enzyme. Furthermore, the present invention relates to an immobilized cap-specific nucleoside 2′-O-methyltransferase, preferably an immobilized Vaccinia virus cap-specific nucleoside 2′-O-methyltransferase. Moreover, the present invention relates to a method for immobilizing said enzymes and to a method of using said enzymes for the addition of a 5′-cap structure to RNAs. Moreover, the present invention relates to an enzyme reactor for performing the capping reaction using said immobilized enzymes and the subsequent separation of the 5′-capped RNA product. In addition, the present invention relates to a kit comprising the capping enzyme and/or the cap-specific nucleoside 2′-O-methyltransferase.